Total Payments
$225.32
2024 Payments
$29.10
Companies
4
Transactions
11
Medicare Patients
3,847
Medicare Billing
$371,256
Payment Breakdown by Category
Food & Beverage$225.32 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $225.32 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $73.96 | 3 | $0 (2024) |
| Celgene Corporation | $69.83 | 4 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.08 | 2 | $0 (2023) |
| PFIZER INC. | $33.45 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29.10 | 2 | ABBVIE INC. ($15.57) |
| 2023 | $196.22 | 9 | Celgene Corporation ($69.83) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.53 | General |
| Category: Neuroscience | ||||||
| 08/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/20/2023 | AbbVie Inc. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $29.44 | General |
| Category: IMMUNOLOGY | ||||||
| 07/19/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/28/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.87 | General |
| Category: Neuroscience | ||||||
| 06/20/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.65 | General |
| Category: Neuroscience | ||||||
| 06/06/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/21/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: IMMUNOLOGY | ||||||
| 01/24/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 834 | 881 | $559,427 | $98,068 |
| 2022 | 22 | 987 | 1,036 | $578,071 | $88,313 |
| 2021 | 19 | 1,135 | 1,205 | $588,955 | $101,808 |
| 2020 | 20 | 891 | 954 | $469,884 | $83,067 |
Total Patients
3,847
Total Services
4,076
Medicare Billing
$371,256
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 83 | 84 | $126,588 | $18,418 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 162 | $37,098 | $15,098 | 40.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 114 | 114 | $152,304 | $11,985 | 7.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $30,515 | $10,306 | 33.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 78 | 80 | $78,080 | $6,294 | 8.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 31 | 31 | $27,342 | $5,931 | 21.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 52 | $15,340 | $5,386 | 35.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 12 | 12 | $18,084 | $4,854 | 26.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 16 | 16 | $21,376 | $4,656 | 21.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Office | 2023 | 12 | 12 | $10,584 | $3,764 | 35.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 15 | 15 | $14,640 | $3,673 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 43 | $6,751 | $2,930 | 43.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 45 | $6,795 | $2,863 | 42.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 16 | 16 | $3,760 | $1,124 | 29.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 40 | 48 | $960.00 | $403.20 | 42.0% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 45 | 45 | $8,370 | $221.06 | 2.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 18 | 21 | $840.00 | $159.81 | 19.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 81 | 81 | $122,067 | $17,498 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 146 | 160 | $36,640 | $14,590 | 39.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 144 | 145 | $193,720 | $14,156 | 7.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 75 | 75 | $26,925 | $9,104 | 33.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 76 | 76 | $74,176 | $5,692 | 7.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 28 | 29 | $25,578 | $5,579 | 21.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 49 | 49 | $10,731 | $3,898 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 50 | $7,850 | $3,334 | 42.5% |
About Dr. Gloria Caruso, M.D
Dr. Gloria Caruso, M.D is a Specialist healthcare provider based in Bloomingdale, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164442877.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gloria Caruso, M.D has received a total of $225.32 in payments from pharmaceutical and medical device companies, with $29.10 received in 2024. These payments were reported across 11 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($225.32).
As a Medicare-enrolled provider, Caruso has provided services to 3,847 Medicare beneficiaries, totaling 4,076 services with total Medicare billing of $371,256. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Bloomingdale, IL
- Active Since 07/19/2006
- Last Updated 10/09/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1164442877
Products in Payments
- ZEPOSIA (Drug) $69.83
- ENTYVIO (Biological) $48.08
- RINVOQ (Biological) $44.52
- XELJANZ (Drug) $33.45
- SKYRIZI (Biological) $29.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.